The Technical Analyst
Daxor Corp [DXR]
Exchange: AMEX Industry: Asset Management
Daxor Corp Price, Forecast, Insider, Ratings, Fundamentals & Signals
0.03% $9.55
America/New_York / 10 mai 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 45.23 mill |
| EPS: | 0.140 |
| P/E: | 68.23 |
| Earnings Date: | Mar 25, 2024 |
| SharesOutstanding: | 4.73 mill |
| Avg Daily Volume: | 0.0027 mill |
| RATING 2024-05-10 |
|---|
| A- |
| Buy |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Strong Buy | |
| Return On Asset: | Strong Buy | |
| DE: | Sell | |
| P/E: | Neutral | |
| Price To Book: | Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | n/a | n/a | n/a | |||
| Debt | n/a | n/a | n/a | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 5.55x |
| Company: PE 68.23 | sector: PE 12.30 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0x |
| Company: PE 68.23 | industry: PE -5.64 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 9.21 - 9.90 ( +/- 3.61%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-03-27 | Michel Robert J | Buy | 750 | Daxor Common Stock |
| 2024-03-04 | Feuer Edward | Buy | 1 000 | Daxor Common Stock |
| 2023-12-06 | Michel Robert J | Buy | 120 | Daxor Common Stock |
| 2023-12-01 | Michel Robert J | Buy | 180 | Daxor Common Stock |
| 2023-12-01 | Feldschuh Michael Richard | Buy | 800 | Daxor Common Stock |
| INSIDER POWER |
|---|
| 56.55 |
| Last 97 transactions |
| Buy: 668 992 | Sell: 434 444 |
Forecast:
13:44 - $9.52
Live Trading Signals (every 1 min)
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 |
| Volume Signals | |
|---|---|
| Price | $9.55 (0.03% ) |
| Volume | 0.0003 mill |
| Avg. Vol. | 0.0027 mill |
| % of Avg. Vol | 10.90 % |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For DXR
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
DXR
Daxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was incorporated in 1971 and is headquartered in Oak Ridge, Tennessee.
Latest Press Releases
2024-04-10 08:00:00 - Press Release
Daxor Corporation Announces New Hospital Account At Leading Chicago Hospital
450-bed hospital purchases bva-100 ™ blood volume analyzer to launch h eart failure p rogram
2024-03-25 08:00:00 - Press Release
Daxor Corporation Acquires Volumex® And Megatope® From Its Existing Supplier Along With Glofil® To Enhance Existing Suite Of Diagnostics
Expected to improve margins and increase revenue streams oak ridge, tn, march 25, 2024 (globe newswire) -- daxor corporation (nasdaq: dxr), the global leader in blood volume measurement technology, announces today it has entered into a definitive agreement to acquire exclusive and worldwide rights and intellectual property to manufacture from its existing supplier for volumex and megatope from privately-held iso-tex diagnostics, inc. daxor has also acquired the exclusive rights to glofil, a drug that measures glomerular filtration rate (gfr), which iso-tex has been selling directly to its customer base. daxor projects the acquisitions to be cash flow positive and accretive to earnings immediately upon transfer of the manufacturing.
2024-03-22 08:00:00 - Press Release
Daxor Corporation To Hold Investor Call Discussing Fiscal Year 2023 Financial Results And Corporate Update On March 25, 2024
Oak ridge, tn, march 22, 2024 (globe newswire) -- daxor corporation (nasdaq: dxr), the global leader in blood volume measurement technology, announces an investor call to be held on monday, march 25, 2024, at 4:00 p.m. et.
2024-03-18 14:18:00 - Press Release
Daxor Corporation Ceo And President Michael Feldschuh Provides Corporate Update In Letter To Shareholders
Oak ridge, tn, march 18, 2024 (globe newswire) -- daxor corporation (nasdaq: dxr), the global leader in blood volume measurement technology today issued a corporate update in a letter to shareholders filed in its certified shareholder report on form n-csr on march 15, 2023 from ceo & president, michael feldschuh.
2024-03-18 14:18:00 - Press Release
Daxor Corporation Reports Increase In Nav To $7.08 Per Share And 31.8 Percent Increase In Unaudited Revenue Of Operating Division For The Year Ended December 31, 2023
Strong start to 2024 with unaudited revenue climbing 229.1% in first two months of 2024 yoy oak ridge, tn, march 18, 2024 (globe newswire) -- daxor corporation (nasdaq: dxr), the global leader in blood volume measurement technology, announces today the filing of its annual report to shareholders on form n-csr, disclosing its schedule of portfolio holdings as of december 31, 2023. management reported a nav of $7.08 per share for fiscal 2023 versus $6.75 for the comparable period in 2022.
Latest News
2024-03-25 20:05:25 - Seeking Alpha
Daxor Corporation (DXR) Q4 2023 Earnings Call Transcript
2023-09-07 09:15:00 - GlobeNewsWire
Daxor Corporation to Present at the H.C. Wainwright 25th Annual Global Investment Conference
Oak Ridge, TN, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, announces today that CEO and President Michael Feldschuh will present at the H.C. Wainwright 25th Annual Global Investment Conference being held on September 11 - 13, 2023 at the Lotte New York Palace.
2023-03-06 15:04:06 - Seeking Alpha
Daxor Corporation (DXR) Q4 2022 Earnings Call Transcript
Daxor Corporation (NASDAQ:DXR ) Q4 2022 Results Conference Call March 2, 2023 9:00 AM ET Company Participants Scott Gordon - President, Core IR Michael Feldschuh - CEO Robert Michel - CFO Conference Call Participants Anthony Vendetti - Maxim Group Evan Greenberg - Legend Cap Operator Ladies and gentlemen, thank you for standing by. Good morning and welcome to the Daxor Corp. Fiscal Year 2022 Financial Results and Corporate Update Conference call.
2022-09-06 17:05:00 - GlobeNewsWire
Daxor Corporation to Attend the H.C. Wainwright 24th Annual Global Investment Conference
Oak Ridge, TN, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, announces today that CEO and President Michael Feldschuh will attend the H.C. Wainwright 24th Annual Global Investment Conference being held on September 12 – 14, 2022 at the Lotte New York Palace.
2022-08-26 19:06:05 - Seeking Alpha
Daxor Corporation (DXR) Q2 2022 Earnings Call Transcript
Daxor Corporation (NASDAQ:DXR ) Q2 2022 Earnings Conference Call August 25, 2022 4:30 PM ET Company Participants Scott Gordon - President and Co-Founder of CORE IR Michael Feldschuh - CEO & President Robert Michel - CFO Conference Call Participants Anthony Vendetti - Maxim Group Edward Wu - Ascendiant Capital Michael Samuels - Berthel Fisher Operator Good afternoon, and welcome to the Daxor Corporation First Half 2022 Financial Results and Corporate Update Conference Call. At this time, all participants are in listen-only mode.
2022-08-24 16:40:00 - GlobeNewsWire
Daxor Corporation to Report First Half 2022 Financial Results on Thursday, August 25, 2022, and Provide Corporate Update
2022-05-12 08:00:00 - GlobeNewsWire
Daxor Corporation to Present at the H.C. Wainwright & Company Global Investment Conference
NEW YORK, May 12, 2022 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, announces today that President and CEO Michael Feldschuh will present at the H.C. Wainwright Global Life Investment Hybrid Conference which is being held from May 23-26th at the Fontainebleau Miami Beach Hotel, Miami FL.
2022-01-06 08:00:00 - GlobeNewsWire
Daxor Corporation to Present at the H.C. Wainwright BioConnect 2022 Virtual Conference
Oak Ridge, TN, Jan. 06, 2022 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE: DXR), the global leader in blood volume measurement technology, today announces that CEO and President Michael Feldschuh will present a corporate overview at the H.C. Wainwright BioConnect 2022 Virtual Conference, which is taking place on January 10 – 13, 2022.
2021-10-01 08:30:00 - GlobeNewsWire
Daxor Corporation Receives $200K Matching Fund Award from Launch Tennessee
The SBIR/STTR Matching Fund Grant Will Advance the Company's Innovation and Commercialization Efforts, and Job Creation
2021-09-14 08:30:00 - GlobeNewsWire
Daxor Corporation Presents New Data Validating the Benefit of the BVA-100® Blood Test for Heart Failure Patients at Key Scientific Society Meeting
Data from Three New Studies and Two Ongoing Trials Presented at the Heart Failure Society of America Annual Scientific Meeting 2021 Data Highlight Importance of Blood Volume Analysis in Providing Appropriate, Personalized Care to Patients with Heart Failure